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Abstract
Background: Neuroendocrine tumor (NET) with adrenocorticotropic hormone (ACTH) secretion are very rare. To
our knowledge, no follow-up study is published for ACTH-secreting NET, regardless of the primary site, to show
second occurrence of tumor after a long follow-up, following resection of primary tumor.
Case presentation: Here, we describe a 49-year-old-man with cushingoid feature, drowsiness and quadriparesis came
to emergency department at December 2005. Laboratory tests revealed hyperglycemia, metabolic alkalosis, severe
hypokalemia, and chemical evidence of an ACTH-dependent hypercortisolism as morning serum cortisol of 57 μg /dL
without suppression after 8 mg dexamethasone suppression test, serum ACTH level of 256 pg/mL, and urine free
cortisol of > 1000 μg /24 h. Imaging showed only bilateral adrenal hyperplasia, without evidence of pituitary adenoma
or ectopic ACTH producing tumors. Importantly, other diagnostic tests for differentiating Cushing disease (CD) from
ectopic ACTH producing tumor, such as inferior petrosal sinus sampling (IPSS), corticotropin releasing hormone (CRH)
stimulation test, octreotide scan or fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan were not
available in our country at that time. Therefore, bilateral adrenalectomy was performed that led to clinical and
biochemical remission of hypercortisolism and decreased ACTH level to < 50 pg/mL, findings suggestive of a primary
focus of NET in adrenal glands. After 11 years uncomplicated follow up, the ACTH level elevated up to 341 pg/mL and
re-evaluation showed a 2 cm nodule in the middle lobe of the right lung. Surgical excision of the pulmonary nodule
yielded a carcinoid tumor with positive immunostaining for ACTH; leading to decrease in serum ACTH level to 98 pg/
mL. Subsequently after 7 months, serum ACHT levels rose again. More investigation showed multiple lung nodules
with metastatic bone lesions accompanied by high serum chromogranin level (2062 ng/mL), and the patient managed
as a metastatic NET, with bisphosphonate and somatostatin receptor analogues.
Conclusion: This case of surgically-treated NET showing a secondary focus of carcinoid tumor after one decade of
disease-free follow-up emphasizes on the importance of long-term follow-up of ACTH-secreting adrenal NET.
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Introduction
Neuroendocrine tumors (NETs) are a family of hetero-
geneous neoplasms of epithelial or neuronal/neuroecto-
dermal origin, arising from any anatomical site. These
neoplasms, express different proteins including markers
of general neuroendocrine differentiation and site-
specific markers such as hormones and transcription
factors [1]. The overall incidence of NET is ~ 2 per 100,
000 cases per year [2]. The ectopic adrenocorticotropic
hormone (ACTH)-dependent Cushing syndrome (CS),
an occasional manifestation of NETs, is caused most
commonly by small cell lung carcinomas, following by
bronchial carcinoid tumors, thymic carcinoids, islet cell
tumor of pancreas, medullary thyroid carcinoma, and
rarely pheochromocytoma [2]. However, data regarding
the prevalence of ACTH-secreting NETs are limited. In
a tertiary referral center, among 918 patients with thor-
acic and gastroenteropancreatic NETs, the prevalence of
ACTH-producing NET was 3.2% [3] .
To the best of our knowledge, this is the first case of
ACTH-secreting NET, with improvement of symptoms
and signs of hypercortisolism and normalization of the
serum ACTH level after bilateral adrenalectomy, with
long term of remission, complicated by the recurrence
of the tumor in the lung with multiple bone metastasis
after 11 years.
Case presentation
A 49-y-old man admitted to an emergency department
in 21 December 2005, with the complaint of drowsiness
and quadriparesia. On admission, the patient was
afebrile and had a blood pressure of 200/110 mmHg,
pulse rate of 95/min and, a body mass index of 32 kg/
m2. On physical examination, he had facial plethora,
central obesity, pitting edema of limbs, without evidence
of purple striae or hyperpigmentation. On neurologic
examination, cranial nerves function was intact, prox-
imal and distal force were 3/5, and tendon reflexes were
diminished. Other examination was unremarkable. His
problem was started a year ago with weight gain (4 kg),
fatigue, proximal muscle weakness, easy bruising and
hypertension. He didn’t complaint paroxysmal hyperten-
sion, headache, palpitation, or sweating. He had been
smoker of 20 pack/y for almost 30 years, with no previ-
ous medical or surgical history, and no family history for
endocrine disease. Initial work up on admission revealed
marked hypokalemia (2.1 mEq/L), metabolic alkalosis
(pH: 7.58, HCO3:57.2 mEq/L) and blood glucose of 330
mg/dL. Electrocardiogram showed long QT interval
(0.52 s), inverted T wave, and prominent U wave in pre-
cordial leads. The patient admitted in coronary care unit.
According to high suspicious of CS, 24-h urine for urin-
ary free cortisol (UFC) was collected. Laboratory data re-
vealed UFC greater than 1000 μg/24 h (reference value:
50–149 μg/24 h), serum ACTH 257 pg/mL at 8 AM (ref-
erence value: 9–46 pg/mL), and morning serum cortisol
57 μg/dL (reference value:5.5–26.1 μg/dL) (Table 1). Fol-
lowing 8 mg oral administration of dexamethasone at 11
PM, no suppression was found at morning serum corti-
sol level (67 μg/dL). Considering ACTH-dependent CS,
dynamic pituitary magnetic resonance imaging (MRI)
was done that did not show pituitary adenoma; spiral
chest and abdominopelvic computed topographies (CT)
Table 1 Laboratory tests of the patient on the first admission in
December 2005




Hemoglobin 13.4 g/dL 13.5–17.5 g/dL
Platelets 248,000mm3 150,000–450,000/mm3
Biochemistry
B.U.N. 19 mg/dL 8–20 mg/dL
Creatinine 1.51 mg/dL 0.5–1.5 mg/dL
sodium 144mEq/L 132–145mEq/L
potassium 2mEq/L 3.8–5.6 mEq/L
ALT 36 IU/L 5–40 IU/L
AST 21 IU/L 5–40 IU/L
LDH 857 U/L 250–500 U/L
Fasting glucose 330mg/dL 70–110mg/dL
Hb A1C 5.30% 4.1–6.6%
Total cholesterol 177 mg/dL less than 200mg/dL
TG 180mg/dL 50–190mg/dL
calcium 8.5 mg/dL 8.6–10.6 mg/dL
magnesium 2.5 mg/dL 1.6–3 mg/dL
PH 7.59 7.35–7.45
PCO2 61.1 mmHg 35–45mmHg
HCO3− 57.2 mmol/L 24–28mmol/L
Hormonal assay
Cortisol 8 a.m. 57 μg/dL 5.5–26.1 μg/dL
Urine free cortisol 1020 μg/24 h 40–145 μg/24 h
ACTH 256 pg/mL 0–50 pg/mL
TSH 0.3 μIU/mL 0.23–4.84 μIU/mL
Total T4 6.3 μg/dL 4.5–12.5 μg/dL
Testosterone 1.2 ng/ 2.3–10 ng/mL
LH 0.4 IU/L 0.63–7.89 IU/L
Aldosterone (supine) 94 ng/mL 10–105 ng/mL
Direct Renin 3.8 μIU/mL 0.5–1.9 μIU/mL
WBC White blood cells, BUN Blood urea nitrogen, ALT Alanine
aminotransferase, AST Aspartate aminotransferase, LDH Lactate
dehydrogenase, TG Triglycerides, ACTH Adrenocorticotropic hormone, TSH
Thyroid stimulating hormone, LH Luteinizing hormone
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were unremarkable, except of the significant enlarge-
ment of bilateral adrenal glands. Treatment with ketoco-
nazole, 200 mg every 12 h, was initiated to control
hypercortisolism. According to persistent hypokalemia
despite excess potassium supplement (> 120 mEq/day) 2
days after starting ketoconazole, the patient was sched-
uled for bilateral trans-abdominal open adrenalectomy
on 28 December 2005. The weights and sizes of excised
right and left adrenal glands were 18 g, 6× 3× 0.8 cm and
20 g, 6× 3.5× 1 cm, respectively. Microscopic examin-
ation revealed diffuse adrenocortical hyperplasia. Three
days after surgery, 24-h UFC, morning serum cortisol
and ACTH levels decreased to 27 μg/24-h, 2.2 μg/dL, 44
pg/mL, respectively, furthermore blood pressure and
serum potassium and glucose levels were normalized.
The patient was discharged on daily dose of 5 mg pred-
nisolone and 0.1 mg fludrocortisone. All signs and symp-
toms of CS were resolved gradually during 4months,
and 24-h UFC was consistently less than 4 μg/24-h. He
remained asymptomatic and during annual laboratory
follow-ups results of serum ACTH and UFC were unre-
markable, i.e. ACTH < 50 pg/mL, UFC < 4 μg/24-h. In
November 2016, serum ACTH began to rise, and in No-
vember 2017 reached to 341 pg/mL (Fig. 1). Reassess-
ment for ectopic ACTH producing NET was performed
using spiral neck, chest, and abdominopelvic CT-scans. A
2 cm mass in the middle lobe of the right lung was found
and dynamic contrast enhanced pituitary MRI and
Technetium-99m-octerotide scan were normal (Fig. 2). A
CT-guided biopsy from the lung mass showed a tumor
composed of solid nests of small monotonous cells with
no atypia or mitotic activity, suggesting an ACTH-
producing carcinoid tumor. Histologic examination of the
resected right middle lobe revealed carcinoid tumor with-
out involvement of hilar, subcarinal and intralobar lymph
nodes. Immunohistochemical (IHC) staining showed dif-
fuse positivity for chromogranin, synaptofysine, and
ACTH (Fig. 3); the proliferation marker of Ki-67 was posi-
tive in 1% of the neoplastic cells, with the final diagnosis
of ACTH-producing carcinoid tumor. Postoperative
course was uneventful, and serum ACTH level decreased
to less than 100 pg/mL. Approximately 7months later,
serum ACTH level had an upward trend to 171 pg/mL
(Fig. 1). Spiral chest CT scan revealed at least 2 nodules
measuring up to 5mm in the lower lobe of the right lung.
There were also suspicious lytic bone lesions in thoraco-
abdominal CT. Subsequently, whole body bone scan with
TC99 was performed suggesting multiple metastatic bone
lesions at clavicles, ribs, iliac, temporal and parietal bones
(Fig. 4). CT-guided left iliac wing biopsy revealed thick
sclerotic osteoid tissue, without neoplastic involvement,
IHC staining for cytokeratin and chromogranin were
negative, although serum chromogranin level was re-
ported 2062 ng/mL (reference value: < 100 ng/mL). Hence,
according to the high level of the chromogranin, as well as
the presence of nodular lesions in the lung, the patient
was managed as a metastatic NET, treatment with bis-
phosphonate and somatostatin receptor analogous was
started.
Discussion
Here, we reported a unique case of ACTH-dependent
CS due to ACTH-producing NET of adrenal glands ori-
gin that resolved after bilateral adrenalectomy, and the
patient was on remission for more than a decade follow-
up with unremarkable ACTH level. Then rising serum
Fig. 1 Trend of serum ACTH level from December 2005 to 2020
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ACTH level indicating the recurrence of other ectopic
ACTH secreting NET. Finally, the presence of second
focus of NET in lung accompanied by high level of
serum chromogranin and bone metastasis was
confirmed.
NETs are uncommon tumors, and due to their insidious
presentation and difficulty in localization, the diagnosis
and treatment of them are challenging [4]. Traditionally,
they categorize from well-differentiated to poorly-
differentiated tumors according to their histologic feature,
lymphovascular invasion, mitotic activity, ki67 labeling
index, presence of metastasis, and their hormonal
production. Furthermore, the behavior of NET can change
during years from low to high grade and from functional
to non-functional or vice versa [5].
Here, we discussed the potential scenario for our case.
At presentation, there was a possible small size tumor in
adrenal medulla (i.e. a small focus of NET). After bilat-
eral adrenalectomy, a significant decrease in ACTH level
occurred from 257 to 44 pg/ml and remained in less
A
B
Fig. 2 Spiral chest computed tomography of the patient in 2017. a
mediastinal view, b parenchymal view of lung nodule (arrow)
Fig. 3 Histopathology of lung nodule biopsy: a small monotonous
epithelial cells, without atypia or mitotic activity (H&E staining,
magnification × 100); b strong positive staining of tumor cells for
ACTH (magnification × 100)
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than 50 pg/ml for more than a decade (Fig. 1), the issue
indicated the source of ACTH production was poten-
tially attributable to the adrenal glands. The absence of
NET in the pathology of severely hyperplasic adrenal
glands was due to low suspicion for its diagnosis, prepar-
ing inadequate sections on gross and microscopic exam-
ination of the resected tissue, and limited availability of
IHC for ACTH staining in 2005. This ACTH-producing
NET in adrenal medulla cured after bilateral adrenalec-
tomy and reappeared as a secondary focus of potentially
high-grade NET involving lung with bone metastasis
after 11 years. ACTH-production is one of the paraneo-
plastic manifestation of lung cancers [6]. Actually, small
cell lung carcinoma and lung carcinoid are associated
with ACTH secretion in a rate of 4.5 and 5%, respect-
ively [7]. In our review of literature, ACTH-secreting
pheochromocytoma is very rare and, only 58 cases have
been reported till 2018 [8]. Moreover, according to
International Agency for Research on Cancer (IARC)
and World Health Organization (WHO) expert consen-
sus proposal, poorly differentiated neuroendocrine tu-
mors (neuroendocrine carcinoma) do not occur in the
adrenal or in paraganglia [9]. The majority of ACTH-
secreting pheochromocytoma involved unilateral adrenal
glands, excluding three cases of bilateral pheochromocy-
toma, in the background of multiple endocrine neopla-
sia, MEN IIa [8, 10]. In a retrospective study by Henrik
et al. from all 164 cases of CS during 10 years, just two
of them were ectopic ACTH-secreting tumors arising
from adrenal medulla [11]. One of them was a 44 years
old woman with established ACTH-dependent CS
(serum cortisol: 24.3 μg /dL, ACTH: 44 pg/mL), with a
heterogeneous 5 cm large left adrenal mass, underwent
left adrenalectomy. The patient didn’t have any symptom
or sign of pheochromocytoma except hypertension crisis
during surgery. After surgery, the symptoms of hyper-
cortisolism resolved accompanied by normal serum
levels of ACTH and cortisol. Adrenal pathology revealed
just adrenal medullary hyperplasia and IHC staining
expressed ACTH in 10% of the adrenal medullary cells.
Actually, in small adrenal mass (less than 1 cm) differen-
tiating pheochromocytoma from adrenal medullary
hyperplasia is so difficult [12, 13]. In our case we did not
exclude the possibility of adrenal medullary hyperplasia
with ACTH producing activity, as well. To our know-
ledge, no follow-up study is published for ACTH-
secreting NET, regardless of the primary site, to show
recurrence of tumor after a long-time following resec-
tion of primary tumor.
Since, we followed the patient using just serum ACTH
level, and imaging study did not perform till elevated
ACTH level was detected, the chronological scenario for
occurring of lung NET in our case was not cleared. One
possibility is that the lung foci of NET were present long
time before elevated ACTH level was detected i.e. con-
version of non-functional NETs to functioning tumors.
There are many types of NETs with different behavior
from slowly to quickly growth pattern [8].
Regardless of the mentioned scenario, at present we
have a patient with lung NET and bone metastasis,
hence the patient underwent treatment by Sandostatin
LAR 20 microgram every 20 day.
Fig. 4 Whole body scan with 99 m technetium. Multiple bone metastases in clavicles, ribs, iliac, temporal, and parietal bone
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Important limitations should be considered in our case
presentation. In 2005, other diagnostic tests for differen-
tiating CD from ectopic ACTH producing tumor such
as inferior petrosal sinus sampling (IPSS), corticotropin
releasing hormone (CRH) stimulation test, octreotide
scan or fluorodeoxyglucose (FDG)-positron emission
tomography (PET) scan were not available in our coun-
try. The first limited series of performing IPSS have been
reported in Iran in 2020 [14, 15].
Conclusion
We reported a unique case of ACTH-secreting NET in
adrenal with resolving hypercortisolism and normalization
of ACTH level after bilateral adrenalectomy and recur-
rence of the second ACTH producing NET in the lung
after more than a decade follow-up. We emphasized the
importance of long-term follow-up of ACTH-secreting
adrenal NETs that cured with surgery to diagnose second-
ary focus of NET, whether functional or non-functional.
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